Core Insights - AbbVie's innovative drug, Venclexta® (generic name: Venetoclax), has been launched exclusively on JD Health in 10mg and 50mg formulations, providing a new treatment option for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients who have undergone at least one treatment and have 17p deletion [1][3] - This marks the second indication approved for Venclexta® in China, following its approval for acute myeloid leukemia (AML) [1] - JD Health aims to leverage its capabilities as the "first station for new specialty drugs" to enhance the accessibility of innovative medications for patients [1] Industry Context - CLL and SLL are mature B lymphocyte clonal proliferative tumors primarily affecting the elderly, often considered different clinical manifestations of the same disease, characterized by abnormal accumulation of B lymphocytes in the bone marrow, blood, and lymphatic tissues, which impairs normal hematopoiesis [3] - The incidence of CLL/SLL is expected to rise with the aging population in China, and the 17p deletion is found in over 30% of relapsed or refractory CLL cases, representing a high-risk factor for patient prognosis [3] - Venclexta® is the first BCL-2 inhibitor approved globally and in China for targeted therapy in CLL patients, selectively binding and inhibiting B-cell lymphoma 2 (Bcl-2) protein, aiding in the restoration of tumor cell apoptosis [3] - The drug specifically targets the high-risk group of CLL/SLL patients with 17p deletion, offering an effective and safe new treatment option for this population [3] - JD Health plans to continue optimizing the online accessibility of innovative specialty drugs through collaboration with global pharmaceutical partners, aiming to build a more efficient ecosystem for innovative drug services for users [3]